CA3233319A1 - Resmetirom for reducing liver volume - Google Patents
Resmetirom for reducing liver volume Download PDFInfo
- Publication number
- CA3233319A1 CA3233319A1 CA3233319A CA3233319A CA3233319A1 CA 3233319 A1 CA3233319 A1 CA 3233319A1 CA 3233319 A CA3233319 A CA 3233319A CA 3233319 A CA3233319 A CA 3233319A CA 3233319 A1 CA3233319 A1 CA 3233319A1
- Authority
- CA
- Canada
- Prior art keywords
- resmetirom
- subject
- prodrug
- less
- liver
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163248634P | 2021-09-27 | 2021-09-27 | |
| US63/248,634 | 2021-09-27 | ||
| PCT/US2022/044826 WO2023049491A1 (en) | 2021-09-27 | 2022-09-27 | Resmetirom for reducing liver volume |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3233319A1 true CA3233319A1 (en) | 2023-03-30 |
Family
ID=83900064
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3233319A Pending CA3233319A1 (en) | 2021-09-27 | 2022-09-27 | Resmetirom for reducing liver volume |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US20240408102A1 (enExample) |
| EP (2) | EP4578499A3 (enExample) |
| JP (1) | JP2024536126A (enExample) |
| KR (1) | KR20240073926A (enExample) |
| CN (1) | CN118251221A (enExample) |
| AR (1) | AR127165A1 (enExample) |
| AU (1) | AU2022348966A1 (enExample) |
| CA (1) | CA3233319A1 (enExample) |
| CL (1) | CL2024000886A1 (enExample) |
| IL (1) | IL311670A (enExample) |
| MX (1) | MX2024003967A (enExample) |
| TW (1) | TW202337470A (enExample) |
| WO (1) | WO2023049491A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024251233A1 (zh) * | 2023-06-08 | 2024-12-12 | 成都微芯药业有限公司 | PPAR全激动剂联合THR-β激动剂在抗代谢相关疾病中的用途 |
| JP2026521649A (ja) * | 2023-06-22 | 2026-06-30 | マドリガル ファーマシューティカルズ インコーポレイテッド | ＴＨＲ－βアゴニストを用いて肝障害を治療するためのバイオマーカーおよび関連する使用 |
| KR20260000642A (ko) * | 2024-06-25 | 2026-01-05 | 연세대학교 산학협력단 | Usp10 억제제를 유효성분으로 포함하는, 간섬유증 또는 간섬유증 관련 질환의 예방 또는 치료용 조성물 |
| WO2026107045A1 (en) * | 2024-11-12 | 2026-05-21 | Madrigal Pharmaceuticals, Inc. | Resmetirom for use in treating cardiomyopathy and/or related heart failure and portal hypertension |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE480524T1 (de) | 2005-07-21 | 2010-09-15 | Hoffmann La Roche | Pyridazinonderivate als schilddrüsenhormon- rezeptoragonisten |
| US8076334B2 (en) | 2007-09-20 | 2011-12-13 | Hoffmann-La Roche Inc. | Prodrugs of thyroid hormone analogs |
| ES2795450T3 (es) | 2012-09-17 | 2020-11-23 | Madrigal Pharmaceuticals Inc | Procedimiento para sintetizar análogos de hormonas tiroideas y polimorfos de los mismos |
| MX394463B (es) | 2016-10-18 | 2025-03-19 | Madrigal Pharmaceuticals Inc | Métodos para tratar trastornos del hígado o trastornos lipídicos con un agonista de thr-beta. |
| TW202615431A (zh) | 2018-07-02 | 2026-04-16 | 美商瑪德瑞高製藥公司 | ２－（３，５－二氯－４－（（５－異丙基－６－側氧基－１，６－二氫噠嗪－３－基）氧）苯基）－３，５－二側氧基－２，３，４，５－四氫－１，２，４－三嗪－６－腈之固體型式 |
| CA3111025C (en) * | 2018-09-06 | 2023-10-31 | Galmed Research And Development Ltd | Combination therapy for the treatment of liver disease |
| EP4775207A2 (en) | 2018-12-05 | 2026-07-15 | Viking Therapeutics, Inc. | Compositions for the treatment of fibrosis |
| CA3195960A1 (en) | 2020-10-23 | 2022-04-28 | Madrigal Pharmaceuticals, Inc. | Process for the preparation of 6-(4-nitro-phenoxy)-2h-pyridazin-3-one and 6-(4-amino-phenoxy)-2h-pyridazin-3-one derivatives as intermediates of thyroid hormone analogues |
-
2022
- 2022-09-27 TW TW111136510A patent/TW202337470A/zh unknown
- 2022-09-27 IL IL311670A patent/IL311670A/en unknown
- 2022-09-27 EP EP24212126.7A patent/EP4578499A3/en active Pending
- 2022-09-27 MX MX2024003967A patent/MX2024003967A/es unknown
- 2022-09-27 US US18/695,572 patent/US20240408102A1/en active Pending
- 2022-09-27 CN CN202280075697.1A patent/CN118251221A/zh active Pending
- 2022-09-27 EP EP22793025.2A patent/EP4408428A1/en not_active Withdrawn
- 2022-09-27 JP JP2024519112A patent/JP2024536126A/ja active Pending
- 2022-09-27 CA CA3233319A patent/CA3233319A1/en active Pending
- 2022-09-27 AR ARP220102600A patent/AR127165A1/es unknown
- 2022-09-27 KR KR1020247013928A patent/KR20240073926A/ko active Pending
- 2022-09-27 WO PCT/US2022/044826 patent/WO2023049491A1/en not_active Ceased
- 2022-09-27 AU AU2022348966A patent/AU2022348966A1/en active Pending
-
2024
- 2024-03-26 CL CL2024000886A patent/CL2024000886A1/es unknown
-
2025
- 2025-11-12 US US19/386,839 patent/US12661361B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20260069598A1 (en) | 2026-03-12 |
| IL311670A (en) | 2024-05-01 |
| JP2024536126A (ja) | 2024-10-04 |
| MX2024003967A (es) | 2024-06-03 |
| US12661361B2 (en) | 2026-06-23 |
| AU2022348966A1 (en) | 2024-04-11 |
| US20240408102A1 (en) | 2024-12-12 |
| CN118251221A (zh) | 2024-06-25 |
| EP4408428A1 (en) | 2024-08-07 |
| CL2024000886A1 (es) | 2024-08-30 |
| KR20240073926A (ko) | 2024-05-27 |
| WO2023049491A1 (en) | 2023-03-30 |
| AR127165A1 (es) | 2023-12-27 |
| EP4578499A2 (en) | 2025-07-02 |
| TW202337470A (zh) | 2023-10-01 |
| EP4578499A3 (en) | 2025-09-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP4578499A2 (en) | Resmetirom for reducing liver volume | |
| US11400072B2 (en) | Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy | |
| JP6941109B2 (ja) | Ｆｘｒアゴニストを使用するための方法 | |
| RU2743075C2 (ru) | Способы применения агонистов fxr | |
| CN105764498A (zh) | 纯合家族型高胆固醇血症的治疗 | |
| CN105228622B (zh) | 用于治疗多发性硬化的PPARγ激动剂 | |
| JP2018526407A (ja) | 特定の患者集団において神経変性障害を処置する方法 | |
| TW200918049A (en) | Compounds useful as medicaments | |
| US20200276178A1 (en) | Combinations comprising fxr agonists | |
| WO2024041596A1 (zh) | 苯妥英钠作为线粒体自噬诱导剂的用途 | |
| JP2017531012A (ja) | Ｓａｒｍを使用した泌尿器系障害の治療方法 | |
| JP2015509931A (ja) | 医薬的な組み合わせ | |
| US20260097039A1 (en) | Methods for treating a fatty liver disease | |
| US9226926B2 (en) | Therapeutic agent for lower urinary tract disease | |
| HK40128789A (en) | Resmetirom for reducing liver volume | |
| KR101893551B1 (ko) | 치료 방법 | |
| US20240423992A1 (en) | Biomarkers for treating liver disorders with thr-b agonists and related uses | |
| US20250161326A1 (en) | Combination therapy | |
| CN114401745A (zh) | 包含fxr激动剂的治疗 | |
| WO2025250918A1 (en) | Novel compositions | |
| JP2023522062A (ja) | 代謝異常を治療するためのベンズイミダゾール化合物 | |
| JP2005075747A (ja) | 痒み抑制剤 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD Year of fee payment: 2 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20241213 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20241213 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250919 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250919 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20251027 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD Year of fee payment: 4 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20260701 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20260702 |